Prostate enlargement treatment shifts toward minimally invasive options as patients struggling with persistent symptoms of benign prostatic hyperplasia (BPH) face tough choices between continued medication and surgical risks.
For many aging men, medication may lose effectiveness over time or cause side effects such as dizziness, orthostatic hypotension, retrograde ejaculation, or even acute angle-closure glaucoma associated with alpha-blockers. While surgical resection or enucleation effectively improves urinary flow, it carries burdens including bleeding, recovery time, potential changes in ejaculation, and general anesthesia risks for older adults or those with chronic conditions like diabetes, hypertension, or cardiovascular disease.
To reduce these burdens, minimally invasive treatments such as the Urolift procedure have emerged as a notable alternative. Urolift involves inserting an endoscopic instrument through the urethra and using special metal sutures to bind and secure the obstructing prostate tissue to the sides.
Because it preserves normal prostate tissue without cutting, laser ablation, or thermal energy, the procedure can be performed under local or conscious sedation in about 10 to 20 minutes. Patients often avoid postoperative catheterization and can be discharged on the same day, allowing for a fast return to daily life.
The European Association of Urology (EAU) recommends Urolift for men who wish to preserve ejaculatory function and have a prostate volume of less than 70 mL without severe enlargement.
Furthermore, a 2026 study analyzing 210 patients with an average age of 74.3 who underwent Urolift across 14 medical institutions in Japan showed that the International Prostate Symptom Score (IPSS) improved by 36.9 percent and quality-of-life scores improved by 43.3 percent at 12 months post-procedure, alongside significant increases in maximum urinary flow rate.
Related reading